激素受体阳性/HER2阴性早期乳腺癌内分泌治疗研究进展
Research Advances in Endocrine Therapy for Hormone Receptor-Positive/HER2-Negative Early Breast Cancer
摘要
Abstract
Hormone receptor(HR)-positive/HER2-negative early breast cancer is the most common subtype of breast cancer,and endocrine therapy serves as the cornerstone of adjuvant treatment.In recent years,with the publication of key clinical trials such as SOFT,TEXT,and monarchE,and breakthroughs in novel agents studies like lidERA,the endocrine therapy strategy for HR-positive/HER2-negative early breast cancer has evolved toward increased precision and intensity.This article systematically reviews the latest advances in endocrine therapy,focusing on the consolidation of ovarian function suppression as a standard for high-risk premenopausal patients with updated follow-up evidence,the benefit-risk assessment of extended endocrine therapy,and the current application and interdrug differences of CDK4/6 inhibitors in the adjuvant setting.This manuscript also addresses existing challenges,including optimizing treatment-related quality of life and precisely identifying beneficiary populations,and briefly introduces the clinical trial progress of novel agents,such as oral selective estrogen receptor degraders.Furthermore,it outlines evidence-based strategies for ovarian protection during chemotherapy and fertility preservation for young patients.This review aims to provide clinicians with a comprehensive perspective,balancing the pursuit of maximal efficacy with patients'long-term quality of life and individualized needs.关键词
乳腺肿瘤/激素受体阳性/人表皮生长因子受体2/内分泌治疗/卵巢功能抑制/CDK4/6抑制剂/卵巢保护/生育力保存Key words
Breast neoplasms/Hormone receptor positive/HER2/Endocrine therapy/Ovarian function suppression/CDK4/6 inhibitor/Ovarian protection/Fertility preservation分类
医药卫生引用本文复制引用
黄文钦,杨亚龙,吴新红,Matteo LAMBERTINI,郑红梅..激素受体阳性/HER2阴性早期乳腺癌内分泌治疗研究进展[J].肿瘤防治研究,2026,53(3):169-175,7.基金项目
Talent Project of Hubei Cancer Hospital(No.2025HBCHLHRC002 （）
No.2025HBCHHHRC005 （）
No.2025HBCHQHRC018) （）
Chutian Talent Project(No.CTYC002) （No.CTYC002）
Wu Jieping Fund Project(No.320.6750.2024-21-5 （）
No.320.6750.2025-21-13) （）
Hubei Province Medical Youth Talent Program(No.Eweitong[2023]65) （No.Eweitong[2023]65）
National Key Specialized Construction Project(No.HBCHBBC-A01) （No.HBCHBBC-A01）
Hubei Cancer Hospital Intramural Research Program(No.2025HBCHYN24 （）
No.2025HBCHYN35) 湖北省肿瘤医院人才项目(2025HBCH-LHRC002 （）
2025HBCHHHRC005 （）
2025HBCHQHRC018) （）
楚天英才项目(CTYC002) （CTYC002）
吴阶平基金(320.6750.2024-21-5 （）
320.6750.2025-21-13) （）
湖北省医学青年拔尖人才项目(鄂卫通[2023]65号) （鄂卫通[2023]65号）
湖北省肿瘤医院乳腺癌国家临床重点专科建设项目(HBCHBBC-A01) （HBCHBBC-A01）
湖北省肿瘤医院院内科研项目(2025HBCHYN24 （）
2025HBCHYN35) （）
